The panel of experts take evolving pharmacologics into account as they review the best treatment strategies for spinal muscular atrophy (SMA).
Expert clinicians highlight current unmet needs surrounding the treatment of Alzheimer disease.
The autonomic disorders and sleep medicine specialist at Stanford University spoke about the overlap of autonomic disorders in sleep medicine, an often underrepresented portion of the sleep medicine field. 
Moving forward following failed studies in Alzheimer disease and improving how the condition is managed in the future.
Moving into the setting of gene therapy, key opinion leaders consider the potential of AVXS-101 (onasemnogene abeparvovec) for spinal muscular atrophy (SMA).
An in-depth review of mechanisms linked to the pathogenesis of Alzheimer disease, including amyloid and tau.
Taking into account data from several clinical trials, the panel discusses oral therapy for spinal muscular atrophy (SMA) with risdiplam.
Ronald C. Petersen, MD, PhD, discusses the relationship between genetics and the risk for developing Alzheimer disease, as well as highlights efforts of the Generation Program.
Experts shed light on the data behind the first FDA approval for spinal muscular atrophy (SMA), nusinersen, and consider what was learned through its approval.
SAP Partner Banner